Study Information
Status: Active, Not Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
Not Specified
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
Study COVALENT-112 is a 52-week, Phase 2 trial designed to examine beta-cell function, insulin sensitivity, and both glucose and lipid metabolism in participants with T1D treated with BMF-219. BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about COVALENT-112